HONG KONG, Aug. 4, 2025 /PRNewswire/ -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped...
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped...
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1
Spearheaded by Pacifica Christian High School's SurfersWhoServe, dozens of students will gather July 29 to advocate for continued leadership in ocean safety and environmental...
Expanded collaboration adds additional notifiable disease and respiratory targets impacting poultry production to Alveo's molecular testing platform, delivering lab-quality answers in under an hour...
July 19, 2025: Update
This outbreak investigation is ongoing. The public health notice will be updated as the investigation evolves.
OTTAWA, ON, July 19, 2025 /CNW/...
BioBond Adhesives Partners with All in One Professional Services to Enhance LTHC Homeless Services Facility
LAFAYETTE, Ind., July 17, 2025 /PRNewswire/ -- BioBond Adhesives, Inc. ("BioBond"),...
July 15, 2025: Update
OTTAWA, ON, July 15, 2025 /CNW/ -
At a glance
Do not consume, use, sell, serve or distribute recalled:
Rea brand Genoa Salami Sweet (Lots: 5035...